Evolution of the Average Target: Sandoz Group AG

Evolution of the Target Price: Sandoz Group AG

Changes in Analyst Recommendations: Sandoz Group AG

62d23d0d3.yPF69BvftGR0Nw3LI_Xc_PcTSOdCKAZmY02PB_7R50E._Z4lkyqG2xYdW0OEG5Cwhs5FDdF7HHQ_In76Qoe9pReZxRy3WKn-Izx4TA~097ef0ba5d41f8e551240476daf6d88a
03/07 Jefferies slightly cuts its target on Sandoz Zonebourse
29/06 Swiss Stocks Open Week Upbeat; Sandoz Group Gains MT
25/06 AlphaValue/Baader Europe Downgrades Sandoz Group to Reduce, Lifts PT MT
24/06 William O'Neil & Co Starts Sandoz Coverage at Buy MT
16/06 Sandoz retreats despite price target upgrade Zonebourse
02/06 AlphaValue/Baader Europe Upgrades Sandoz Group to Add, Trims PT MT
01/06 Sandoz slips, despite bullish comments from AlphaValue Zonebourse
01/06 Sandoz Edges Lower Despite Positive Commentary from AlphaValue Zonebourse
01/06 AlphaValue/Baader Europe Upgrades Sandoz Rating, Price Target on 'Strong' Biosimilar Moat MT
30/05 Sandoz: Gravity-defying Sandoz; fundamental valuation metrics revisited Alphavalue
05/05 Jefferies Raises Its Target on Sandoz Group Zonebourse
04/05 Berenberg Lifts Estimates for Sandoz Amid Potential for Diminishing Headwinds MT
29/04 Sandoz: Remarkable biosimilar performance runs the show Alphavalue
29/04 Swiss stocks - Factors to watch on April 29 RE
14/04 Swiss stocks - Factors to watch on April 14 RE
01/04 Goldman Sachs Kicks off Sandoz Group Coverage at Buy MT
23/03 RBC Capital Downgrades Sandoz Group to Sector Perform, Boosts PT MT
23/03 Sandoz Rating Downgraded as RBC Sees Fewer Near-term Biosimilar Opportunities; Price Target Up MT
17/03 Sadif Investment Analytics Starts Sandoz Coverage with Buy Rating MT
04/03 Berenberg Says FY26 'Year for Delivery' for Sandoz; Price Target Up MT
26/02 Barclays Downgrades Sandoz Group to Equalweight, Lifts PT MT
25/02 Sandoz: Healthy 2026 outlook raises hopes for a mid-term guidance upgrade Alphavalue
17/02 AlphaValue/Baader Europe Lifts Sandoz Price Target, Notes Biosimilar Momentum MT
16/02 Swiss Stocks Begin Week Upbeat as Economy Rebounds; Zurich Insurance Up MT
16/02 Sandoz: Growth prospects that even some Big Pharmas may envy Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+2.8%
+1.93%
-0.2%
+3.82%
+7.07%
+20.73%
-0.27%
-1.01%
-2.19%
+17.4%
Average +5.01%
Weighted average by Cap. +3.84%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
85.04USD
Average target price
87.42USD
Spread / Average Target
+2.80%
High Price Target
102.20USD
Spread / Highest target
+20.18%
Low Price Target
67.08USD
Spread / Lowest Target
-21.12%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

AlphaValue/Baader Europe
William O'Neil & Co.
alphavalue Abhishek Raval
Goldman Sachs
RBC Capital Markets
Sadif Investment Analytics
Barclays
Jefferies & Co.
ODDO BHF
Octavian AG
UBS
Berenberg Bank
Morningstar
Stifel Nicolaus
JPMORGAN James Gordon
MORGAN STANLEY Thibault Boutherin
BERENBERG Victoria Lambert
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
85.04USD
Average target price
87.42USD
Spread / Average Target
+2.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SDZ Stock
  4. Consensus Sandoz Group AG